A Study of MG-K10 in Subjects With Atopic Dermatitis

Summary

This study evaluates the preliminary efficacy of MG-K10 in subjects with moderate to severe asthma, and provides a basis for the design and dosing regimen of phase III clinical trials.

Timeline

Start

2022-08-31

Primary completion

2023-09-22

Completion

2024-05-26

Outcome

Met primary endpoint

release “MG-K10（comekibart）人源化单抗注射液用于治疗中重度特应性皮炎患者的 II期临床研究达到主要临床终点” mabgeek.com ↗

Drugs

Indications